CannaVcell Sciences Inc. (CSE:CNVC) (“CannaVcell”) announced last Thursday, the first production of Cannabis cells in suspension, with a cannabinoid profile identical to that of the original cannabis plant – without the need to grown the plant itself. The achievement was possible using the breakthrough and patented BioHarvest’s technology (CannaVcell is the worldwide exclusive licensee of the technology for cannabis application). (See NR: www.cannavcell.com).

cannavcell


Figure 1 presents identical THCA and CBDA profiles for cannabis cells grown in liquid suspension as those found in actual cannabis flowers.

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6168/48318_7e0eb946e4f9fb71_006full.jpg

cannavcell

Figure 2 shows Cannabis cells powder that was produced in a small scale bioreactor (true picture).

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/6168/48318_7e0eb946e4f9fb71_005full.jpg

The Bioharvest technology, called biofarming, mirrors nature without any solvent extraction, genetic modification or synthetic molecular processing. In regard to Cannabis, biofarming end result is a cannabis powder with the identical composition of cannabinoids as those found in the cannabis plant. The original plant is used only once to collect its cannabis cells with the active ingredients that are subsequently perpetually reproduced with the same quality and consistency.

Dr. Yochi Hagay, CTO of BioHarvest. Dr. Hagay added, “We are the first company in the world that has been able to grow cannabis cells that produce six (6) different types of cannabinoids THCA, THC, CBDA, CBD, CBN, CBC, all of which are identical to the cannabinoids produced in the relevant Cannabis flower.”

cannavcell

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/48318_cv2.jpg

COPY/PASTE REGISTRATION LINK: https://attendee.gotowebinar.com/register/8500294009813134092

Dr. Zaki Rakib, Co-Founder & CEO: “This achievement marks a turning point in the Cannabis Community. The revolution is here, is now! I invite the public and the Cannabis Industry, to joint me for a live webinar this Wednesday October 2nd, 2019 at 8:00 AM Pacific Daylight Time.”

About Canna-V-Cell Sciences Inc.

Based in Vancouver BC, Canna-V-Cell Sciences Inc. (CNVC) is the exclusive Cannabis worldwide licensee of the proprietary and patent protected BioHarvest technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. By adopting this technology and building adequate cells production capacity, Canna-V-Cell’s objective is to become the lead- ing supplier of Cannabis for both the medicinal and recreational legal use.

Canna-V-Cell Sciences Inc.
Dr. Zaki Rakib
Co-Founder & CEO

For further info, please contact: Email: inquiries@cannavcellsciences.ca Local: 604.373.4774 Toll Free: 833.727.4774

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things, risks and uncertainties relating to the fact that the Company would require additional funds in order to construct a commercial biochamber facility and risks related to the adaption of the BioHarvest technology to cannabis. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

cannavcell

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/48318_cv4.jpg

Click here to connect with Canna-V-Cell Sciences Inc. (CSE:CNVC) for an Investor Presentation.

Source

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less